March 1 (Reuters) - ADVENTRX Pharmaceuticals Inc:
* Receives refuse to file letter from FDA on ANX-530 new drug application
* Says plans to meet with the FDA as soon as possible to discuss its response
* FDA said data in initial submission was insufficient to support
commercially-viable expiration dating period
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Receives refuse to file letter from FDA on ANX-530 new drug application
* Says plans to meet with the FDA as soon as possible to discuss its response
* FDA said data in initial submission was insufficient to support
commercially-viable expiration dating period
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
